RESUMEN
Opioid-related death and overdose have now reached epidemic proportions. In response to this public health crisis, the National Institutes of Health (NIH) launched the Helping to End Addiction Long-term InitiativeSM, or NIH HEAL InitiativeSM, an aggressive, trans-agency effort to speed scientific solutions to stem the national opioid public health crisis. Herein, we describe two NIH HEAL Initiative programs to accelerate development of non-opioid, non-addictive pain treatments: The Preclinical Screening Platform for Pain (PSPP) and Early Phase Pain Investigation Clinical Network (EPPIC-Net). These resources are provided at no cost to investigators, whether in academia or industry and whether within the USA or internationally. Both programs consider small molecules, biologics, devices, and natural products for acute and chronic pain, including repurposed and combination drugs. Importantly, confidentiality and intellectual property are protected. The PSPP provides a rigorous platform to identify and profile non-opioid, non-addictive therapeutics for pain. Accepted assets are evaluated in in vitro functional assays to rule out opioid receptor activity and to assess abuse liability. In vivo pharmacokinetic studies measure plasma and brain exposure to guide the dose range and pretreatment times for the side effect profile, efficacy, and abuse liability. Studies are conducted in accordance with published rigor criteria. EPPIC-Net provides academic and industry investigators with expert infrastructure for phase II testing of pain therapeutics across populations and the lifespan. For assets accepted after a rigorous, objective scientific review process, EPPIC-Net provides clinical trial design, management, implementation, and analysis.
Asunto(s)
Dolor Crónico/epidemiología , Dolor Crónico/terapia , Ensayos Clínicos Fase II como Asunto , Recursos en Salud/tendencias , National Institutes of Health (U.S.)/tendencias , Animales , Dolor Crónico/economía , Ensayos Clínicos Fase II como Asunto/economía , Ensayos Clínicos Fase II como Asunto/métodos , Evaluación Preclínica de Medicamentos/economía , Evaluación Preclínica de Medicamentos/métodos , Recursos en Salud/economía , Humanos , National Institutes of Health (U.S.)/economía , Dimensión del Dolor/economía , Dimensión del Dolor/métodos , Dimensión del Dolor/tendencias , Estados Unidos/epidemiologíaRESUMEN
Christian Lienhardt and co-authors discuss the conclusions of the PLOS Medicine Collection on advances in clinical trial design for development of new tuberculosis treatments.
Asunto(s)
Antituberculosos/uso terapéutico , Ensayos Clínicos como Asunto/métodos , Tuberculosis/tratamiento farmacológico , Antituberculosos/farmacología , Ensayos Clínicos como Asunto/economía , Ensayos Clínicos Fase II como Asunto/economía , Ensayos Clínicos Fase II como Asunto/métodos , Ensayos Clínicos Fase III como Asunto/economía , Ensayos Clínicos Fase III como Asunto/métodos , Desarrollo de Medicamentos , Evaluación Preclínica de Medicamentos , Humanos , Cumplimiento de la Medicación , Factores de Tiempo , Investigación Biomédica Traslacional , Poblaciones VulnerablesRESUMEN
There is a pressing need to address the current major gaps in epilepsy treatment, in particular drug-resistant epilepsy, antiepileptogenic therapies, and comorbidities. A major concern in the development of new therapies is that current preclinical testing is not sufficiently predictive for clinical efficacy. Methodologic limitations of current preclinical paradigms may partly account for this discrepancy. Here we propose and discuss a strategy for implementing a "phase II" multicenter preclinical drug trial model based on clinical phase II/III studies designed to generate more rigorous preclinical data for efficacy. The goal is to improve the evidence resulting from preclinical studies for investigational new drugs that have shown strong promise in initial preclinical "phase I" studies. This should reduce the risk for expensive clinical studies in epilepsy and therefore increase the appeal for funders (industry and government) to invest in their clinical development.
Asunto(s)
Anticonvulsivantes/uso terapéutico , Ensayos Clínicos Fase II como Asunto , Evaluación Preclínica de Medicamentos , Drogas en Investigación/uso terapéutico , Epilepsia/tratamiento farmacológico , Estudios Multicéntricos como Asunto , Animales , Anticonvulsivantes/efectos adversos , Ensayos Clínicos Fase I como Asunto/economía , Ensayos Clínicos Fase II como Asunto/economía , Ahorro de Costo , Evaluación Preclínica de Medicamentos/economía , Resistencia a Medicamentos , Drogas en Investigación/efectos adversos , Humanos , Estudios Multicéntricos como Asunto/economía , Apoyo a la Investigación como Asunto/economía , Resultado del TratamientoRESUMEN
Pediatric oncology is an unrivaled success story in the recent history of medicine. This success is mostly based on a persistent refinement of evidence based therapeutic concepts. With that regard physicians and their staff are highly experience in the conduct of prospective evidence based trials and are therefore competent partners for the pharmaceutical industry. In times of personalized medicine the individual target population is diminishing and the borders of indications are not more disease based. A situation that requires new concepts from the industry. Therefore children with cancer could benefit early from the current developments as well as the pharmaceutical industry could benefit from the legislative incentives through highly recruiting and well conducted prospective trials. Pivotal is a functional platform of communication in order to maintain a close dialogue between academia and pharmaceutical companies.
Asunto(s)
Antineoplásicos/uso terapéutico , Ensayos Clínicos Fase I como Asunto/tendencias , Ensayos Clínicos Fase II como Asunto/tendencias , Conducta Cooperativa , Industria Farmacéutica/tendencias , Drogas en Investigación/uso terapéutico , Comunicación Interdisciplinaria , Leucemia/tratamiento farmacológico , Neoplasias/tratamiento farmacológico , Medicina de Precisión/tendencias , Centros Médicos Académicos/economía , Centros Médicos Académicos/legislación & jurisprudencia , Antineoplásicos/efectos adversos , Niño , Ensayos Clínicos Fase I como Asunto/economía , Ensayos Clínicos Fase I como Asunto/legislación & jurisprudencia , Ensayos Clínicos Fase II como Asunto/economía , Ensayos Clínicos Fase II como Asunto/legislación & jurisprudencia , Análisis Costo-Beneficio/economía , Análisis Costo-Beneficio/legislación & jurisprudencia , Análisis Costo-Beneficio/tendencias , Industria Farmacéutica/economía , Industria Farmacéutica/legislación & jurisprudencia , Drogas en Investigación/efectos adversos , Drogas en Investigación/economía , Europa (Continente) , Predicción , Accesibilidad a los Servicios de Salud/economía , Accesibilidad a los Servicios de Salud/legislación & jurisprudencia , Accesibilidad a los Servicios de Salud/tendencias , Necesidades y Demandas de Servicios de Salud/economía , Necesidades y Demandas de Servicios de Salud/legislación & jurisprudencia , Necesidades y Demandas de Servicios de Salud/tendencias , Humanos , Terapia Molecular Dirigida/economía , Terapia Molecular Dirigida/tendencias , Programas Nacionales de Salud/economía , Programas Nacionales de Salud/legislación & jurisprudencia , Programas Nacionales de Salud/tendencias , Medicina de Precisión/economía , Estudios ProspectivosRESUMEN
Since the publication of the results of phase I dose-finding studies, an extensive phase II and III clinical study programme has been undertaken to study the clinical efficacy and tolerability of the quinazoline folate analogue raltitrexed ('Tomudex'), a novel direct and specific inhibitor of thymidylate synthase. Two international phase III trials, studies 3 and 12, have compared raltitrexed 3 mg m(-2) with 5-fluorouracil (5-FU) plus low-dose leucovorin (LV) (Mayo regimen) or high-dose LV (Machover regimen) respectively. A North American study (study 10) was originally set up to compare two raltitrexed dosage arms (3.0 and 4.0 mg m[-2]) with 5-FU and low-dose LV, but the 4.0 mg m(-2) arm was discontinued prematurely because of excessive toxicity. Minimum follow-up times for studies 3, 10 and 12 were 15.5, 12 and 9 months, respectively (for data other than survival), with corresponding survival follow-up times of 26, 12 and 17 months. Objective response rates were similar for raltitrexed and 5-FU + LV, and palliative improvements were seen to a similar extent with both treatments in all phase III studies. Survival was statistically similar for raltitrexed and 5-FU + LV in both studies 3 and 12. Raltitrexed was, however, associated with inferior survival to 5-FU + low-dose LV in study 10, but there appears to be evidence that this was linked to an unconscious effect on investigator behaviour of early toxicity problems in this trial, in that patients appeared to be withdrawn from raltitrexed treatment without progression or protocolled toxicity. Moreover, it appeared that 5-FU + LV patients were continued on treatment after disease progression. 5-FU-based therapy was associated with a higher incidence of mucositis than raltitrexed in all studies, with the attainment of statistical significance in studies 3 and 12. Elevations in hepatic transaminase levels were seen with raltitrexed, but these are thought to be of no clinical significance. Overall, much greater levels of toxicity were seen with 5-FU + LV than with raltitrexed in early treatment cycles. In addition, retrospective UK audit data have shown the monthly cost of raltitrexed therapy to be similar to that of Mayo and continuous infusion 5-FU regimens, and appreciably lower than that of the de Gramont regimen of 5-FU (bolus + 22-h infusion) + high-dose LV. Thus, raltitrexed is an effective alternative to 5-FU-based therapy in patients with advanced colorectal cancer, with an acceptable and, unlike 5-FU, predictable toxicity profile. In particular, patients receiving raltitrexed may benefit from the minimization or avoidance of mucositis, and both patients and healthcare providers may find the convenient administration schedule of the drug advantageous.